Exploring the Effective Components and Mechanism of Action of Japanese Ardisia in the Treatment of Autoimmune Hepatitis Based on Network Pharmacology and Experimental Verification

Japanese Ardisia is widely used as a hepatoprotective and anti-inflammatory agent in China. However, the active ingredients in Japanese Ardisia and their potential mechanisms of action in the treatment of autoimmune hepatitis (AIH) are unknown. The pharmacodynamic substance and mechanism of action of Japanese Ardisia in the treatment of AIH were investigated using network pharmacology and molecular docking technology in this study. Following that, the effects of Japanese Ardisia were evaluated using the concanavalin A (Con A)-induced acute liver injury rat model. The active ingredients and targets of Japanese Ardisia were searched using the Traditional Chinese Medicine Systems Pharmacology database, and hepatitis-related therapeutic targets were identified through GeneCards and Online Mendelian Inheritance in Man databases. A compound–target network was then constructed using Cytoscape software, and enrichment analysis was performed using gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Molecular docking technology was used to simulate the docking of key targets, and the AIH rat model was used to validate the expression of key targets. Nineteen active chemical components and 143 key target genes were identified. GO enrichment analysis revealed that the treatment of AIH with Japanese Ardisia mainly involved DNA–binding transcription factor binding, RNA polymerase II-specific DNA transcription factor binding, cytokine receptor binding, receptor-ligand activity, ubiquitin-like protein ligase binding, and cytokine activity. In the KEGG enrichment analysis, 165 pathways were identified, including the lipid and atherosclerotic pathway, IL-17 signaling pathway, TNF signaling pathway, hepatitis B pathway, and the AGE–RAGE signaling pathway in diabetic complications. These pathways may be the key to effective AIH treatment with Japanese Ardisia. Molecular docking showed that quercetin and kaempferol have good binding to AKT1, IL6, VEGFA, and CASP3. Animal experiments demonstrated that Japanese Ardisia could increase the expression of AKT1 and decrease the expression of CASP3 protein, as well as IL-6, in rat liver tissues. This study identified multiple molecular targets and pathways for Japanese Ardisia in the treatment of AIH. At the same time, the effectiveness of Japanese Ardisia in treating AIH was verified by animal experiments.


Introduction
Autoimmune hepatitis (AIH) is a common liver disease worldwide, seen in both men and women, but predominantly in women. According to epidemiological surveys, the

Screening of Active Compounds
Oral bioavailability (OB) is the fraction of an orally administered drug that reaches systemic circulation. This is an important consideration for bioactive molecules used as therapeutic agents. Drug likeness (DL) qualitatively assesses the capacity of a molecule to become an orally administered drug based on its bioavailability [19]. The main active components of Japanese Ardisia were obtained by searching the TCMSP database. Nineteen

Screening of Active Compounds
Oral bioavailability (OB) is the fraction of an orally administered drug that reaches systemic circulation. This is an important consideration for bioactive molecules used as therapeutic agents. Drug likeness (DL) qualitatively assesses the capacity of a molecule to become an orally administered drug based on its bioavailability [19]. The main active components of Japanese Ardisia were obtained by searching the TCMSP database. Nineteen molecules with OB ≥ 30% and DL ≥ 0.18 were identified as bioactive compounds [20], as shown in Table 1.

Compound Target Interaction Network
The information on the main bioactive components and corresponding targets in Japanese Ardisia were obtained from the TCMSP database (TCMSP, https://lsp.nwu.edu. cn/tcmsp.php, accessed on 14 November 2021). After screening to remove invalid gene IDs, the targets downloaded from the GeneCards (http://www.genecards.org, accessed on 14 November 2021), OMIM databases (OMIM, http://www.omim.org, accessed on 14 November 2021), and TTD (http://db.idrblab, accessed on 14 November 2021) were crossed with those from the TCMSP database to obtain potential targets for the treatment of AIH in Japanese Ardisia. The obtained data are presented as a Venn diagram ( Figure 2). There were 5724 autoimmune hepatitis gene targets, of which 153 were potential targets related to the drug Japanese Ardisia. The drug-related genes and disease-specific targets were analyzed, and 143 key target genes were identified. The targets of the active ingredients of Japanese Ardisia are shown in Table 2.

Core Genes of the PPI Network
The common targets of Japanese Ardisia and autoimmune hepatitis were imported into the STRING protein interaction database (https://string-db.org, accessed on 15 November 2021) to construct the PPI network ( Figure 3A). The top 30 target proteins analyzed by R software (https://www.r-project.org/ accessed on 15 November 2021) are shown in Figure 3B. The intersections of differential genes between Japanese Ardisia active ingredient targets and autoimmune hepatitis disease targets were imported into Cytoscape 3.7.0 (http://www.cytoscape.org, accessed on 15 November 2021) for topological analysis. The key targets were sorted according to the degree value, with higher degree values indicating nodes that were more central in the network and more important. Through the PPI protein interaction network, the disease-related targets are found, and the degree value is greater than the median by screening twice to find key targets. Thus, the key target genes for autoimmune hepatitis treatment mainly included AKT1, IL6, VEGFA, CASP3, JUN, MYC, etc. ( Figure 3C).

Compound Target Interaction Network
The information on the main bioactive components and corresponding targets in Japanese Ardisia were obtained from the TCMSP database (TCMSP, https://lsp.nwu.edu.cn/tcmsp.php, accessed on 14 November 2021). After screening to remove invalid gene IDs, the targets downloaded from the GeneCards (http://www.genecards.org, accessed on 14 November 2021), OMIM databases (OMIM, http://www.omim.org, accessed on 14 November 2021), and TTD (http://db.idrblab, accessed on 14 November 2021) were crossed with those from the TCMSP database to obtain potential targets for the treatment of AIH in Japanese Ardisia. The obtained data are presented as a Venn diagram ( Figure 2). There were 5724 autoimmune hepatitis gene targets, of which 153 were potential targets related to the drug Japanese Ardisia. The drug-related genes and disease-specific targets were analyzed, and 143 key target genes were identified. The targets of the active ingredients of Japanese Ardisia are shown in Table 2.

Network Pharmacology Visualization of Japanese Ardisia
The target PPI information obtained from the STRING protein interaction database was imported into Cytoscape 3.7.0 software (http://www.cytoscape.org, accessed on 15 November 2021), and the common targets between Japanese Ardisia, its active components, and autoimmune hepatitis were visualized. The data were merged into a component-target network diagram via the merge function in Cytoscape 3.7.0 to obtain the network diagram of 'Japanese Ardisia-component-gene-autoimmune hepatitis' (Figure 4).

Network Pharmacology Visualization of Japanese Ardisia
The target PPI information obtained from the STRING protein interaction database was imported into Cytoscape 3.7.0 software (http://www.cytoscape.org, accessed on 15 November 2021), and the common targets between Japanese Ardisia, its active components, and autoimmune hepatitis were visualized. The data were merged into a componenttarget network diagram via the merge function in Cytoscape 3.7.0 to obtain the network diagram of 'Japanese Ardisia-component-gene-autoimmune hepatitis' (Figure 4).

GO Functional Enrichment Analysis
The 20 GO nodes with the greatest number of annotated proteins were selected for display. These nodes mainly involved DNA-binding transcription factor binding, RNA polymerase II-specific DNA binding, cytokine receptor binding, receptor-ligand activity, ubiquitin-like protein ligase binding, cytokine activity, ubiquitin-protein ligase binding, nuclear receptor activity, ligand-activated transcription factor activity, and kinase regulatory activity. The p-values were arranged from largest to smallest, and visual analysis was performed using an advanced bubble graph ( Figure 5). DNA-binding transcription factor binding had the most obvious effect, and the greatest number of genes, followed by RNA polymerase II-specific DNA binding, cytokine receptor binding, receptor-ligand activity, ubiquitin-like protein ligase binding, cytokine activity, and ubiquitin-protein ligase binding. Meanwhile, nuclear receptor activity, ligand-activated transcription factor activity, kinase regulator activity, and other pathways indirectly affected a series of signaling pathways, eventually causing changes in biological processes.

GO Functional Enrichment Analysis
The 20 GO nodes with the greatest number of annotated proteins were selected for display. These nodes mainly involved DNA-binding transcription factor binding, RNA polymerase II-specific DNA binding, cytokine receptor binding, receptor-ligand activity, ubiquitin-like protein ligase binding, cytokine activity, ubiquitin-protein ligase binding, nuclear receptor activity, ligand-activated transcription factor activity, and kinase regulatory activity. The p-values were arranged from largest to smallest, and visual analysis was performed using an advanced bubble graph ( Figure 5). DNA-binding transcription factor binding had the most obvious effect, and the greatest number of genes, followed by RNA polymerase II-specific DNA binding, cytokine receptor binding, receptor-ligand activity, ubiquitin-like protein ligase binding, cytokine activity, and ubiquitin-protein ligase binding. Meanwhile, nuclear receptor activity, ligand-activated transcription factor activity, kinase regulator activity, and other pathways indirectly affected a series of signaling pathways, eventually causing changes in biological processes.

KEGG Pathway Enrichment Analysis
One hundred and sixty-three pathways were identified in the KEGG enrichment analysis. The top 20 signaling pathways mainly involved the lipid and atherosclerosis pathway, Kaposi sarcoma-associated pathway, human cytomegalovirus infection path-

KEGG Pathway Enrichment Analysis
One hundred and sixty-three pathways were identified in the KEGG enrichment analysis. The top 20 signaling pathways mainly involved the lipid and atherosclerosis pathway, Kaposi sarcoma-associated pathway, human cytomegalovirus infection pathway, IL-17 signaling pathway, TNF signaling pathway, hepatitis B pathway, and the AGE-RAGE signaling pathway were involved in diabetic complications ( Figure 6). The results suggest that Japanese Ardisia can be used to treat autoimmune hepatitis through multi-target and multi-pathway regulation.

Molecular Docking
The X-ray crystal structures of the target molecules AKT1, IL6, VEGFA, and CASP3 were obtained from the PDB protein structure database. PyMOL 2.5 was then used to remove water molecules and small molecules with ligand affinity. Subsequently, the protein receptor and ligand files were converted into PDBQT format using AutoDock Tools 1.5.6. AutoDock Vina 1.1.2 was used to characterize the molecular docking and calculate its affinity. The conformation with the highest affinity was selected as the final docking conformation, and PyMOL (https://pymol.org/2/ accessed on 16 November 2021) and Auto-Dock software (https://autodock.scripps.edu/ accessed on 16 November 2021) were used to visualize the docking results in the form of two-dimensional and three-dimensional diagrams (Figure 7). If the binding energy between the molecule and the target protein is negative, the ligand and receptor can spontaneously bind, and if the binding energy is less than −5 kcal/mol, a stable docking structure can be formed [21]. The docking binding energies between quercetin and AKT1, IL6, VEGFA, and CASP3 were −4.91, −5.75, −4.86, and −5.89 kcal/mol, respectively. The docking binding energies between kaempferol and AKT1, IL6, VEGFA, and CASP3 were −5.6, −6.42, −5.04, and −5.12 kcal/mol, respectively. The details are shown in Table 3. The Japanese Ardisia active ingredients quercetin and kaempferol had a good binding ability with the four key targets.

Molecular Docking
The X-ray crystal structures of the target molecules AKT1, IL6, VEGFA, and CASP3 were obtained from the PDB protein structure database. PyMOL 2.5 was then used to remove water molecules and small molecules with ligand affinity. Subsequently, the protein receptor and ligand files were converted into PDBQT format using AutoDock Tools 1.5.6. AutoDock Vina 1.1.2 was used to characterize the molecular docking and calculate its affinity. The conformation with the highest affinity was selected as the final docking conformation, and PyMOL (https://pymol.org/2/ accessed on 16 November 2021) and AutoDock software (https://autodock.scripps.edu/ accessed on 16 November 2021) were used to visualize the docking results in the form of two-dimensional and three-dimensional diagrams (Figure 7). If the binding energy between the molecule and the target protein is negative, the ligand and receptor can spontaneously bind, and if the binding energy is less than −5 kcal/mol, a stable docking structure can be formed [21]. The docking binding energies between quercetin and AKT1, IL6, VEGFA, and CASP3 were and −5.89 kcal/mol, respectively. The docking binding energies between kaempferol and AKT1, IL6, VEGFA, and CASP3 were −5.6, −6.42, −5.04, and −5.12 kcal/mol, respectively. The details are shown in Table 3. The Japanese Ardisia active ingredients quercetin and kaempferol had a good binding ability with the four key targets.  To investigate the efficacy of Japanese Ardisia in the treatment of AIH, we established a Con A-induced immunological liver injury model ( Figure 8A). Firstly, we found that Con A caused changes in body weight, liver weight, and liver coefficients in rats after ten days, with some reversal effect after preadministration of Japanese Ardisia ( Figure 8B). The rats' liver tissue was then taken out and checked for cholestasis. Con A group showed signs of cholestasis and inflammation, and there was some relief from cholestasis after the drug was administered ( Figure 8C). By testing serum markers of liver injury (ALT and AST), the results showed that Con A-induced acute liver injury resulted in a significant increase in ALT and AST levels. In contrast, preadministration of Japanese Ardisia was able to alleviate the altered biochemical levels. (Figure 8D).
Furthermore, HE staining of liver tissues showed that the model group had a large infiltration of inflammatory cells and a large amount of vacuolar-like degeneration of hepatocytes compared to the control group. Liver tissue damage was alleviated after preadministration of Japanese Ardisia ( Figure 8E,F), indicating that the pre-administration of the drug was able to slow down the con A-induced histopathological damage to the liver.  To investigate the efficacy of Japanese Ardisia in the treatment of AIH, we established a Con A-induced immunological liver injury model ( Figure 8A). Firstly, we found that Con A caused changes in body weight, liver weight, and liver coefficients in rats after ten days, with some reversal effect after preadministration of Japanese Ardisia ( Figure 8B). The rats' liver tissue was then taken out and checked for cholestasis. Con A group showed signs of cholestasis and inflammation, and there was some relief from cholestasis after the drug was administered ( Figure 8C). By testing serum markers of liver injury (ALT and AST), the results showed that Con A-induced acute liver injury resulted in a significant increase in ALT and AST levels. In contrast, preadministration of Japanese Ardisia was able to alleviate the altered biochemical levels. (Figure 8D).
Furthermore, HE staining of liver tissues showed that the model group had a large infiltration of inflammatory cells and a large amount of vacuolar-like degeneration of hepatocytes compared to the control group. Liver tissue damage was alleviated after preadministration of Japanese Ardisia ( Figure 8E,F), indicating that the pre-administration of the drug was able to slow down the con A-induced histopathological damage to the liver. Western blot analyses are shown in Figure 9, which revealed that CASP3 and IL-6 protein expression levels were significantly higher (p < 0.01), and AKT1 expression levels were significantly lower (p < 0.01) in the model group compared to the normal control group. CASP3 protein expression was significantly lower (p < 0.01), AKT1 protein expression was significantly higher (p < 0.05), and IL-6 protein expression was significantly lower (p < 0.05) in the Japanese Ardisia administration group after 10 days compared to the model group. (F) Effect of Japanese Ardisia pretreatment on the scoring of liver pathological sections of rats with con A-induced liver injury. Compared with normal group, ** p < 0.01; compared with model group, ## p < 0.01. Note: EJA is an extract of Japanese Ardisia. Data were shown as mean ± SEM (n = 6 per group). Scoring criteria: 0-no necrosis; 1-individual cell necrosis; 2-less than 30% necrosis; 3-30-60% necrosis; 4-greater than 60% necrosis [22].

The Effect of Japanese Ardisia on AKT1, CASP3, and IL-6 Protein Levels
Western blot analyses are shown in Figure 9, which revealed that CASP3 and IL-6 protein expression levels were significantly higher (p < 0.01), and AKT1 expression levels were significantly lower (p < 0.01) in the model group compared to the normal control group. CASP3 protein expression was significantly lower (p < 0.01), AKT1 protein expression was significantly higher (p < 0.05), and IL-6 protein expression was significantly lower (p < 0.05) in the Japanese Ardisia administration group after 10 days compared to the model group. (F) Effect of Japanese Ardisia pretreatment on the scoring of liver pathological sections of rats with con A-induced liver injury. Compared with normal group, ** p < 0.01; compared with model group, ## p < 0.01. Note: EJA is an extract of Japanese Ardisia. Data were shown as mean ± SEM (n = 6 per group). Scoring criteria: 0-no necrosis; 1-individual cell necrosis; 2-less than 30% necrosis; 3-30-60% necrosis; 4-greater than 60% necrosis [22]. Pharmaceuticals 2022, 15, x FOR PEER REVIEW 12 of 18

Discussion
AIH is a chronic inflammatory disease characterized by abnormally high levels of serum autoantibodies, hypergammaglobulinemia, and serum transaminases [23]. With the advancement of medical technology in recent years, AIH has received widespread attention and has gradually become a research hotspot.
Chinese medicine's multi-component and multi-target properties, and thus its holistic and systemic action characteristics, make it unique in its advantages and potential for complex diseases, but this complexity has also limited its application and development.
Cyberpharmacology analyzes drug action at the systemic level and reveals the synergistic mechanism of drug action on the human body, which fits well with the dialectical and holistic view of Chinese medicine theory, and it is expected to bring a breakthrough to Chinese medicine research characterized by a holistic approach, providing new methodological support for Chinese medicine to move from empirical to theoretical science [24][25][26]. We used network pharmacology to create a component-shared target network map in this study to systematically reveal the material basis and molecular mechanism of Japanese Ardisia for the treatment of AIH.
This study provides key information about the anti-hepatitis effect of Japanese Ardisia. The TCMSP database analysis resulted in the screening of 19 active ingredients. 143 effective targets for the treatment of autoimmune diseases were identified using databases, such as GeneCards and OMIM. According to the results of the component-target network analysis, 150 target genes were associated with the drug-disease target intersection. The core genes were AKT1, IL6, VEGFA, and CASP3. AKT1, also known as protein kinase B, regulates a wide variety of cellular functions, including cell proliferation, survival, metabolism, and angiogenesis, in both normal and malignant cells [27]. IL6 is a proinflammatory cytokine with a wide variety of biological functions. It is involved in physiological activities such as the inflammatory response, cellular immunity, and hematopoietic regulation. IL6 plays major roles in the differentiation of B cells into immunoglobulinsecreting cells and antibody production, the activation of T cell proliferation and

Discussion
AIH is a chronic inflammatory disease characterized by abnormally high levels of serum autoantibodies, hypergammaglobulinemia, and serum transaminases [23]. With the advancement of medical technology in recent years, AIH has received widespread attention and has gradually become a research hotspot.
Chinese medicine's multi-component and multi-target properties, and thus its holistic and systemic action characteristics, make it unique in its advantages and potential for complex diseases, but this complexity has also limited its application and development.
Cyberpharmacology analyzes drug action at the systemic level and reveals the synergistic mechanism of drug action on the human body, which fits well with the dialectical and holistic view of Chinese medicine theory, and it is expected to bring a breakthrough to Chinese medicine research characterized by a holistic approach, providing new methodological support for Chinese medicine to move from empirical to theoretical science [24][25][26]. We used network pharmacology to create a component-shared target network map in this study to systematically reveal the material basis and molecular mechanism of Japanese Ardisia for the treatment of AIH.
This study provides key information about the anti-hepatitis effect of Japanese Ardisia. The TCMSP database analysis resulted in the screening of 19 active ingredients. 143 effective targets for the treatment of autoimmune diseases were identified using databases, such as GeneCards and OMIM. According to the results of the component-target network analysis, 150 target genes were associated with the drug-disease target intersection. The core genes were AKT1, IL6, VEGFA, and CASP3. AKT1, also known as protein kinase B, regulates a wide variety of cellular functions, including cell proliferation, survival, metabolism, and angiogenesis, in both normal and malignant cells [27]. IL6 is a pro-inflammatory cytokine with a wide variety of biological functions. It is involved in physiological activities such as the inflammatory response, cellular immunity, and hematopoietic regulation. IL6 plays major roles in the differentiation of B cells into immunoglobulin-secreting cells and antibody production, the activation of T cell proliferation and differentiation, the immune response, and the promotion of inflammatory reactions [28]. IL6 is rapidly synthesized in response to tissue injury or an inflammatory infection. This promotes the body's defense function by stimulating the acute immune response and the hematopoietic system. When the tissue recovers its homeostasis, IL6 synthesis is discontinued [29]. The continuous activation of the IL6 pathway is associated with liver injury and hepatocellular carcinoma [30]. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis, and induces the permeabilization of blood vessels. It is essential for both physiological and pathological angiogenesis. CASP3 is a cysteine aspartate protease that participates in the activation cascade of cysteine proteases. CASP3 plays an important role in inflammation and tumor progression [31]. It is highly expressed in patients with hepatitis B [32], and it regulates cell proliferation and apoptosis [33] and tumor invasion and metastasis [34].
Japanese Ardisia has a therapeutic effect on hepatitis via a mechanism that may be related to key molecules involved in the regulation of autoimmune hepatitis. It inhibits associated inflammatory factors by regulating various signaling pathways, downregulating the concentrations of serum hyaluronic acid and tumor necrosis factor, protecting hepatocytes from injury, reducing liver inflammation, and protecting against lipid peroxidation [35]. Inflammatory stimulation is the cause of many chronic diseases [36]. GO enrichment analysis showed that the anti-hepatitis effect of Japanese Ardisia is related to the inflammatory response, cell cycle regulation, and hormone metabolism. In the KEGG enrichment analysis, 163 pathways were identified, including the lipid and atherosclerosis pathway, IL-17 signaling pathway, TNF signaling pathway, human cytomegalovirus infection pathway, fluid shear stress and atherosclerosis pathway, hepatitis B pathway, and AGE-RAGE signaling pathway in diabetic complications. It can be seen that the pathway is mainly related to oxidative stress, immune regulation, and inflammatory responses, with the AGE-RAGE signaling pathway being closely related to inflammation, which activates the MAPK and NF-KB pathways and interferes with immune and oxidative stress responses [37]. TNF is a key regulator of the inflammatory response, and its receptors TNFR1 and TNFR2 activate complex signaling pathways that lead to a series of inflammatory responses in the vascular endothelium, including thrombosis, leukocyte adhesion, and vascular leakage [38]. The IL-17 signaling pathway is involved in neutrophil infiltration and inflammatory responses and can be restricted by the ACE2 downregulation of the STAT3 pathway, thereby slowing down neutrophil infiltration and inflammation. These pathways may be the key to effective autoimmune hepatitis treatment with Japanese Ardisia, which affects the secretion of certain substances by acting on specific receptors or enzymes, to achieve its therapeutic effect.
The binding interaction between each compound and its receptor was scored by the molecular docking program. A lower score indicated more stable binding between the ligand and its receptor [39,40]. Through the molecular docking of quercetin and kaempferol, the effective components of Japanese Ardisia, with the key targets AKT1, IL6, VEGFA, and CASP3, the docking binding energy and the number of intermolecular hydrogen bonds were obtained. The results showed that quercetin and kaempferol had a good binding ability with the key targets and can spontaneously bind to form a stable binding conformation.
Animal studies have shown that Japanese Ardisia is effective in the treatment of AIH. Western blot analysis revealed that Japanese Ardisia could reduce the expression of CASP3 and IL-6 while increasing the expression of AKT1. These proteins are involved in the AGE-RAGE signaling pathway in diabetic complications. According to this, the Japanese Ardisia may be able to modulate these key targets to achieve therapeutic effects on immune liver injury.
Additionally, there are also limitations to the research at this stage, as network pharmacology techniques can only predict drug composition and targets qualitatively. Highperformance liquid chromatography (HPLC) or ultraviolet spectrophotometry (UV) should be used to determine the plausibility of the screened active ingredients, and this should be combined with pharmacology, pharmacodynamics, and pharmacokinetics to make the screened active ingredients and mechanism of action more convincing.

Screening of Active Ingredients of Japanese Ardisia
The components of Japanese Ardisia were searched in TCMSP (TCMSP, https://lsp. nwu.edu.cn/tcmsp.php, accessed on 14 November 2021) and screened for active compounds by oral bioavailability (OB) and drug similarity (DL), as well as potential targets of action for activity, the active compounds obtained from the screening are presented in the form of a list.

Screening of Target Diseases
GeneCards, OMIM, and TTD were used to identify hepatitis-related gene targets. Specific search parameters, such as the keyword 'autoimmune hepatitis', were used for data collection. Using R 4.0.4 software (https://www.r-project.org/ accessed on 15 November 2021) to remove duplicate regions of gene targets, the intersection of the active ingredient and disease target was obtained and plotted as a Venn diagram.

Target Protein Localization and Interaction Analysis
The cross-targets of Japanese Ardisia in autoimmune hepatitis treatment and prevention were imported into the STRING protein interaction database for analysis. The PPI network was mapped using the Cytoscape 3.7.0 software. A protein-protein interaction (PPI) network was constructed according to proximity centrality, intermediate centrality, and degree value, and the key targets were screened using Cytoscape 3.7.0.

Construction of a Component-Target-Disease Interaction Network of Japanese Ardisia with Autoimmune Hepatitis
The previously acquired common genes and the associated active ingredients were visualized and analyzed using Cytoscape 3.7.0 software.

Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Analysis
The potential targets of Japanese Ardisia for autoimmune hepatitis treatment were imported into the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. GO was selected for enrichment analysis, KEGG was selected for pathway analysis, and the p-value threshold was set at <0.05 to determine the enrichment pathways of key targets. An advanced bubble diagram was constructed from the enrichment results: the smaller the p-value, the higher the enrichment; the larger the bubble, the richer the genes were.

Molecular Docking
The two-dimensional structures of quercetin, kaempferol, and laricitrin were obtained from the TCMSP database and saved as a Mol2 file. AKT serine/threonine kinase 1 (AKT1), interleukin 6 (IL6), vascular endothelial growth factor A (VEGFA), and caspase 3 (CASP3) were selected as the target proteins for molecular docking experiments. The three-dimensional structures of AKT1, IL6, VEGFA, and CASP3 were downloaded from the PDB protein structure database and saved in PDB format [41]. Crystal structures with high resolution and corresponding bioactive ligand complexes were preferentially selected [42]. The structures of the protein macromolecules and small-molecule compounds were imported into AutoDock 4.2.6 software (https://autodock.scripps.edu/ accessed on 16 November 2021) for molecular docking, and the docking results were analyzed using the PyMOL (https://pymol.org/2/ accessed on 16 November 2021) visualization tool.

Animal Experiments
The whole herb of Japanese Ardisia was ground into a coarse powder and kept in a dry, cool environment. A weighed amount of coarse powder was soaked in ten times the amount of water for one night before being decocted twice for 1.5 h each time. The decoctions were combined and concentrated to 1 g/mL (1 mL equals 1 g raw material), the concentrate was centrifuged at 5000 rpm for 15 min, the supernatant was collected and concentrated to 1.5 g/mL (1 mL equals 1.5 g raw material), and the obtained concentrate was refrigerated at 4 • C [43,44].

Animal Grouping and Drug Administration
SPF-grade male SD (Sprague-Dawley) rats, weighing (200 ± 10) g, with six animals per cage were housed in specific pathogen-free facility with a 12 h light and 12 h dark cycle at 22 • C. All mice were randomly divided into three groups, control group (n = 6), con A group (n = 6), and extract of Japanese Ardisia (EJA) (n = 6) groups after being fed adaptively for a week. The control and model groups were given saline, while the administration group was given 36 g/kg of Japanese Ardisia by gavage once daily for 10 days. One hour after the last dose, all groups were given 25 mg/kg con A in the tail vein, except for the control group which was given an equal amount of saline in the tail vein, rats were euthanized 12 h after con A treatment, and their livers were dissected from the rats.
The kits purchased from Nanjing Jiancheng Institute of Biological Engineering were used, and the alanine transaminase (ALT) (Cat.No.C009-2-1) and aspartate transaminase (AST) (Cat.No.C010-1-1) measurements were performed according to the instructions provided by the kit supplier.
All the animals were provided by Hunan Sleek Jingda Laboratory Animal Co. License No. SCXK (Xiang) 2019-0005. Animal welfare and experimental procedures followed the regulations of the Animal Ethics Committee of Guilin Medical College.

Histopathological Section Analysis of Liver
Tissue removed from 2.8.2 was fixed in 4% paraformaldehyde, paraffin sections were embedded, and, finally, the pathological sections were observed by HE staining, and the pathological changes of liver tissues were observed under an electron microscope.

Western Blot
To verify the protein expression level, we extracted protein from rat liver tissue, weighed a certain amount of liver tissue, fully lysed it with RIPA lysis solution (Solarbio, Beijing, China), used SDS-PAGE electrophoresis, and then transferred it to PVDF (Solarbio, Beijing, China) membrane. We then blotted and closed them at room temperature for one hour, and then we incubated them with AKT1 (60203-2, proteintech, Wuhan, China), CASP3 (ab184787, Abcam, Cambridge, UK), IL-6 (ab259341, Abcam, Cambridge, UK), β-actin antibody (66,009, proteintech, Wuhan, China), and incubated them overnight at 4 • C. Then, we incubated them with goat anti-rabbit IgG (H + L) and goat anti-mouse Ig G (H + L) for 1 h at room temperature. The protein bands were visualized using an ECL chemiluminescence kit (Beyotime, Shanghai, China) and quantified under Image J system, version 6.0.

Statistical Analysis
The experimental results are presented as mean ± SEM for each group, with at least three independent experiments. The differences between the treatment and normal groups were analyzed by a one-way analysis of variance using GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, CA, USA). p < 0.05 was used to indicate statistical significance.

Conclusions
In summary, we first performed a network pharmacology and molecular docking approach to elucidate the anti-AIH effects and potential mechanisms of Japanese Ardisia, and finally determined the effect of Japanese Ardisia anti-AIH on the expression of key target proteins by Western blotting analysis. Japanese Ardisia tends to work through the IL-17 signaling pathway, the TNF signaling pathway, the AGE-RAGE signaling pathway in diabetic complications, and other targets such as AKT1, IL-6, and CASP3 to exert drug effects. The potential signaling pathways uncovered in this study lay the theoretical groundwork and point the way for future experimental validation.

Informed Consent Statement: Not applicable.
Data Availability Statement: All data generated or analyzed during this study are included in this published article.